NCT04951648UNKNOWNanonymous

A Randomized Controlled, Open-lable, Phase III, Multicenter Clinical Study of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Sponsor

Source record

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Almonertinib, chemotherapy

Indication / condition

AI-normalized

Non-small Cell Lung Cancer

Intervention

Source record

Almonertinib, chemotherapy

Source & freshness

Source record

NCT ID

NCT04951648

Original source

ClinicalTrials.gov

Source last updated

Jul 07, 2021

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04951648

Title

A Randomized Controlled, Open-lable, Phase III, Multicenter Clinical Study of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Status

UNKNOWN

Phase

PHASE3

Condition raw

Non-small Cell Lung Cancer

Condition normalized

Non-small Cell Lung Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Almonertinib, chemotherapy

Target normalized

Almonertinib, chemotherapy

Interventions

Almonertinib, chemotherapy

Public preview

Source record

To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized Controlled, Open-lable, Phase III, Multicenter Clinical Study of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04951648

Status

UNKNOWN

Phase

PHASE3

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 07, 2021

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04951648

Indication

Non-small Cell Lung Cancer

Modality

small molecule

Target

Almonertinib, chemotherapy

Intervention

Almonertinib, chemotherapy

Source record